



**Medical
Research
Council**

MRC DTP iCASE Workshop

"Taking Research from Bench to Bedside: A Workshop on Intellectual Property and Commercialisation of Life Science Research"

The Robens Suite, Guy's Tower, 30th Floor, King's College London

10:00 AM to 10:05 AM : Welcome from Professor Miraz Rahman, Director iCASE Programme

10:05 AM to 10:15 AM : Introduction of the attendees

10:15 to 11:00 AM: IP – what is it and what is it good for? Dr Ian Durrant, IP & Licensing Manager, King's College London

11:00 AM to 11:30 AM: Lost in Translation, Dr Mike Lyne, Director of Translation, RMID, King's College London

11:30 AM to 12:00 Noon: Commercialisation via a spin-out and a distribution and licensing partnership, Lucie Burgess, Helix Data Innovation Ltd

12:00 PM to 12:30 PM: Panel discussion, Q&A Session

12:30 PM to 1:30 PM: Networking lunch

1:30 PM to 2:00 PM: What is business development? The view from a life sciences charity. Dr Kevin Buchan, Senior Business Development Manager, LifeArc

2:00 PM to 2:30 PM: Newco nuts and bolts – tales from the frontline, Dr Leigh Zawel, Entrepreneur in Residence, Atlas Venture and CSO, Pheon Therapeutics

2:30 PM to 3:00 PM: TBC, Dr Noor Shaker, Founder/CEO, MIT innovators

3:00 PM to 3:15 PM – Coffee Break

3:15 to 3:45 PM: My adventures in discovering and developing novel drugs for treatment of respiratory disease, Professor Clive Page, OBE, Co-founder and previous Chairman of the Board of Verona Pharma plc (A Nasdaq Company)

3:45 PM to 4:15 PM: From lab ideas to healthcare innovations. Why, What, Who, When, Professor Maya Thanou, Co-Founder, CEO and CSO, Apeikon Therapeutics

4:15 PM to 4:45 PM: Panel Discussion

4:45 PM to 5:00 PM: iCASE Translational Fund Competition

Profile of Speakers

Dr Ian Durrant



Ian joined King's in 2021 as IP & Licensing Manager and is responsible for the identification, protection and commercialisation of technologies arising from the academic research in King's various faculties and schools.

Ian obtained his BSc in Biochemistry from the University of Liverpool and then remained there to study for an industry sponsored PhD on the use of enzymology to produce an artificial sweetener. Following his PhD, he did his post-doctoral research on Hog Cholera Virus at the Institute for Animal Health at Pirbright before joining Amersham International, where he worked on the development of novel non-radioactive technologies and was manager of the development team that undertook development of materials and reagents for microarray technology.

In 2004, Ian joined Oxford Immunotec Ltd, as Director of Research. Oxford Immunotec was focused on exploitation and commercialisation of the T-Cell based immune system as a diagnostic platform. Later, as Director of IP, Licensing and Scientific Operations, Ian was responsible for management of the company's IP portfolio (licenses, patents and trademarks). The company held a successful IPO in 2013 on the NASDAQ and was purchased by Perkin Elmer in 2021.

Dr Mike Lyne



Mike is Director of Translation for KCL's Translational Research Office (TRO), part of a new initiative called Innovation@King's which brings together King's TRO, IP & Licensing and Industry Partnership teams under a single structure to provide end-to-end translational support for researchers. For several years prior to this, Mike led translational research management at the NIHR Biomedical Research Centre at Guy's & St. Thomas' NHS Trust and KCL. Mike has over 20 years of experience within both industry and academia covering, amongst other things, advanced cell therapies, drug repurposing and orphan drug development. He holds a PhD in molecular genetics from the University of Exeter.

In his spare time, Mike likes to make traditional wooden bows and arrows, but don't ask him about it unless you have several hours to spare.

Lucie Burgess



Lucie Burgess is a final-year MRC-DTP PhD student. Lucie's research investigates the relationship between exposure to air pollution and greenspace on mental wellbeing outcomes, from both environmental and genetic perspectives. Lucie has over 25 years of experience of leading strategy projects and teams focused on digital, data-driven and tech-enabled innovation. During her career she has delivered strategy, private and public investment, and partnerships, as a management consultant for Deloitte, United Business Media PLC (now Informa), the British Library, the University of Oxford, the Digital Catapult, and charity Diabetes UK. She founded Helix Data Innovation, a science impact accelerator, in 2017.

Dr Leigh Zawel



Leigh Zawel is Chief Scientific Officer at Pheon and an Entrepreneur in Residence at Atlas Venture. Prior to joining Pheon, Leigh was the CSO Small Molecules at Cullinan Oncology and an Executive Partner at MPM Capital and a Senior Investment Partner at Burrage Capital.

Prior to joining Cullinan Oncology and MPM Capital, Leigh was the East Coast Site Head lead at Pfizer's Center for Therapeutic Innovation. Prior to Pfizer, Leigh was the oncology site lead at Merck Research Laboratories Boston, where he was responsible for drug discovery efforts focused on the identification of development candidates for programs in the oncology franchise. Leigh also worked previously at the Novartis Institutes for Biomedical Research/Oncology, where he was an Oncology Group Leader. Leigh has a deep background in identifying and validating oncology drug targets and in transitioning drug discovery programs through lead optimization to Phase 1 clinical trials.

Leigh earned his Ph.D. in the laboratory of Danny Reinberg where he identified and characterized components of the RNA Polymerase II basal transcription machinery. Leigh's postdoctoral training was in the laboratory of Bert Vogelstein and Ken Kinzler and focused on dysregulation of TGFB signaling in cancer. He has published more than 35 scientific publications. He is also an author on 45 patents covering chemical matter, drug combinations, biomarker utility and gene function in areas of apoptosis, inflammation and TGFB signaling.

Dr Noor Shaker



Noor is a serial biotech entrepreneur and recognized healthcare innovator. Prior to Glamorous AI (acquired by X-Chem in October 2021), she was an assistant professor at Aalborg University. Noor is passionate about data and artificial intelligence (AI) and is on a mission to cure disease by pushing the boundaries for what is possible with AI. She has a record of achievements in AI, including numerous papers published in the field and its application to drug discovery, as well as holding a number of AI patents. She sits on AI and diversity advisory boards for prestigious organizations and universities and is a recognized healthcare leader — she was one of the 2018 winners of Innovators Under 35 Europe from MIT Technology Review and named one of BBC's 100 Women of 2019.

Professor Clive Page, OBE, BSc, PhD, FRSB, FBPhs (Hon), FFPM (Hon)



Clive Page is Professor of Pharmacology, King's College London. Clive's main research interests are in the pharmacology of inflammation and respiratory disease, and he has published over 300 scientific papers and book chapters.

Clive was the co-founder and previous Chairman of the Board of Verona Pharma plc, a NASDAQ listed Company developing new drugs for the treatment of Respiratory Diseases. He is a Trustee of the Fraunhofer Institute of Toxicology and Experimental Medicine in Hannover. Clive is also a Non Executive Director of Ananda Developments. Clive started his early career in the Pharmaceutical Industry at Sandoz Ltd, Basel, Switzerland and regularly consults to both Pharmaceutical and Biotech companies. Clive has previously held Non Executive Board positions at Cardiome in Canada, Stirling Products Ltd in Perth, Australia, Immune Regulation Ltd, Epiendo, PreP Biopharma, Babraham Biotechnology Ltd and as a Trustee of the Babraham Institute, Cambridge.

Clive is a former Chairman of the Animal Science Group of the Royal Society of Biology and has contributed widely to the public debate about the use of animals in Research. Clive is currently President of the British Pharmacological Society.

Clive was awarded the Sandoz Prize from the British Pharmacological Society in 1988, The Tanabe Young Investigators Prize from the American College of Clinical Pharmacology in 1996 and the Society of Biology President's Medal in 2012 for "Outstanding Contributions to the Life Sciences". He is a Fellow of the Royal Society of Biology and an Honorary Fellow of the British Pharmacological Society and the Faculty of Pharmaceutical Medicine, Royal College of Physicians. Clive was awarded an OBE for "Services to Pharmacology" in 2017.

Professor Maya Thanou



Maya Thanou is a Professor of Pharmaceutical Nanotechnology in the Institute of Pharmaceutical Science at King's College London. Maya has over 25 years of experience in drug delivery methodologies, has authored over 120 scientific articles and chapters (h index 40) and is a co-inventor on 10 patents/patent applications. Maya is the Vice Chair of the British Society for Nanomedicine. Maya is a co-founder and CEO of a KCL spinout Apeikon Therapeutics. Apeikon's technology aims to make novel solutions for hard to treat tumours. Maya is the co-founder and CSO of a startup AJMmed-i-caps, that develops a combination product for the detection of bowel lesions.